3 or 4 calls ago, Nasrat said that it would be the third quarter of sales under Kirkov that would show the highest growth. That is this coming quarter financials being reported in a month. This together with nearly a month of selling to Prascoe, its not hard to speculate going well above the previous quarter's 14.2 M. I think 20M reported in Feb is not out of the question. Over 100M for the calendar year 2024 would be my guess. After holding this stock through nearly 15 years it seems almost unreal to even say that and believe it, but its very feasible.
Here are my initial estimates based on initial thoughts of Prasco, but launch will give us bit more clarity. Storage expansion mid-year + vigabatrin + small launches + back half needle mover FDA decisions that may or may not be launched to have fiscal impact this calendar year. If Purdue loses case, make way for Elite.
News 
Market Data 
Discover 
